Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
Li Bassi G, Motos A, Fernandez-Barat L, Aguilera Xiol E, Chiurazzi C, Senussi T, Saco MA, Fuster C, Carbonara M, Bobi J, Amaro R, De Rosa F, Comaru T, Yang H, Ranzani OT, Marti JD, Rinaudo M, Comino Trinidad O, Rigol M, Bringué J, Ramirez J, Nicolau DP, Pelosi P, Antonelli M, Blasi F, Artigas A, Montgomery AB, Torres A.
Li Bassi G, et al. Among authors: rigol m.
Crit Care Med. 2019 Jun;47(6):e470-e477. doi: 10.1097/CCM.0000000000003724.
Crit Care Med. 2019.
PMID: 30882478
Secondary outcomes were tracheal secretions P. aeruginosa concentration, clinical variables, lung histology, and development of meropenem resistance. MEASUREMENTS AND MAIN RESULTS: We included five animals into each group. ...Amikacin, amikacin and fosfomycin, and amikacin …
Secondary outcomes were tracheal secretions P. aeruginosa concentration, clinical variables, lung histology, and development of merop …